For instance, it has been reported that high levels of BCL-2 expression were associated with increased sensitivity to ABT-199 in multiple myeloma (MM), but those cells were resistant when BCL-xL or MCL-1 were also expressed [61]. This evidence concerns the gene BCL2 and plasma cell myeloma.